Skyhawk Therapeutics
Beyond's analysis on Skyhawk Therapeutics
- — Skyhawk Therapeutics reports positive 15-month clinical data for Huntington's disease therapy SKY-0515
- — Skyhawk Therapeutics expands its global pivotal Huntington disease trial to the United States, Canada and the United Kingdom, accelerating the path toward potential approval
Recent news mentioning Skyhawk Therapeutics
- — Skyhawk Therapeutics annonce les résultats finaux à quinze mois de l'essai clinique de phase 1/2 du SKY-0515 chez des patients atteints de la maladie de Huntington
- — Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekannt
- — Skyhawk Therapeutics anuncia los resultados finales de 15 meses del ensayo clínico de fase 1/2 de SKY-0515
- — Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
- — Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients